Therapy and Prevention of Atopic Dermatitis in Children and Adolescents

Dear Colleagues,

Atopic dermatitis (AD) is a chronic, complex disease that occurs mainly in children. It is characterized by recurrent eczematous lesions and pruritus that impairs quality of life and daily activities. There are several factors involved in the etiopathogenesis of AD, including epidermal barrier defects, imbalance of the skin microbiome, genetic background and environmental factors. There are multiple systemic and topical treatments that target these pathways that play a critical role in the etiopathogenesis of AD.

It is not clear whether AD can be prevented with various topical agents during the neonatal period. Topical steroids and conventional systemic drugs including ciclosporin and methotrexate and phototherapy are the mainstay of the treatment of AD; on the other hand, new biological therapies, including IL-4, IL-13, and IL-31 inhibitors, as well as Janus kinase inhibitors, are new promising drugs in AD therapy.

This Special Issue entitled "Therapy and Prevention of Atopic Dermatitis in Children and Adolescents'' focuses on publishing high scientific value papers on the prevention of AD in high-risk neonates, secundary prevention measurements of AD in toddlers and infants and school children, skin microbiome diversity and its effect on treatment in children with AD, topical treatment options in pediatric patients with AD, phototherapy in childhood AD and systemic therapies in children with AD.

We look forward to receiving your articles.

Prof. Dr. Regina Fölster-Holst
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• atopic dermatitis
• eczema
• biologics
• children
• phototherapy
• prevention
• neonates
• toddler
• adolescent
• topical
• systemic
• dupilumab
• upadacitinib
• skin microbiome
• jak inhibitors